Volpara to Highlight Growing AI Suite for Mammography at ECR 2024, Including New Lunit Distribution Agreement
WELLINGTON, New Zealand, Feb. 21, 2024 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection and prevention of cancer, announced a distribution agreement to resell Lunit's AI solutions for mammography. Lunit's AI-powered Lunit INSIGHT for early detection of breast cancer will be featured as part of the company's expanded software suite at the 2024 European Congress of Radiology (ECR). The suite also includes tools for assessing breast density, evaluating cancer risk, and ensuring mammography quality.
- Volpara and Lunit® commenced negotiating this distribution agreement prior to entering into a Scheme Implementation Agreement on 14 December 2023 (SIA).
- This distribution agreement is important to Volpara's ongoing business regardless of whether Lunit acquires Volpara as contemplated in the SIA and allows Volpara to sell Lunit's products immediately.
- "The collaboration between Volpara and Lunit marks a significant milestone in the evolution of mammography solutions," said Brandon Suh, CEO of Lunit.
- Volpara will also be presenting "Trustworthy AI for personalised breast cancer screening" in ECR's AI Theatre on Wednesday, February 28 at 16:15.